Literature DB >> 26360262

Bending the curve on psychosis outcomes.

Gregory A Light1, Neal R Swerdlow2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26360262      PMCID： PMC5072396          DOI： 10.1016/S2215-0366(15)00172-8

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN： 2215-0366            Impact factor:   27.083


× No keyword cloud information.
  12 in total

1.  The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study.

Authors:  Eric C Meyer; Ricardo E Carrión; Barbara A Cornblatt; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen; Larry J Seidman
Journal:  Schizophr Bull       Date:  2014-02-18       Impact factor: 9.306

Review 2.  Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

Review 3.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

4.  Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.

Authors:  Gregory A Light; Neal R Swerdlow; Michael L Thomas; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Marlena Pela; Allen D Radant; Larry J Seidman; Richard F Sharp; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; David L Braff; Bruce I Turetsky
Journal:  Schizophr Res       Date:  2014-10-23       Impact factor: 4.939

5.  A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia.

Authors:  Eric Granholm; John R McQuaid; Fauzia Simjee McClure; Lisa A Auslander; Dimitri Perivoliotis; Paola Pedrelli; Thomas Patterson; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

6.  Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.

Authors:  Melissa Fisher; Christine Holland; Michael M Merzenich; Sophia Vinogradov
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

7.  D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.

Authors:  Joshua T Kantrowitz; Scott W Woods; Eva Petkova; Barbara Cornblatt; Cheryl M Corcoran; Huaihou Chen; Gail Silipo; Daniel C Javitt
Journal:  Lancet Psychiatry       Date:  2015-04-28       Impact factor: 27.083

8.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study.

Authors:  Golam M Khandaker; Rebecca M Pearson; Stanley Zammit; Glyn Lewis; Peter B Jones
Journal:  JAMA Psychiatry       Date:  2014-10       Impact factor: 21.596

9.  Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.

Authors:  Ofer Agid; Cynthia O Siu; Steven G Potkin; Shitij Kapur; Eric Watsky; Douglas Vanderburg; Robert B Zipursky; Gary Remington
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

Review 10.  Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review.

Authors:  Tatsuya Nagai; Mariko Tada; Kenji Kirihara; Tsuyoshi Araki; Seiichiro Jinde; Kiyoto Kasai
Journal:  Front Psychiatry       Date:  2013-09-23       Impact factor: 4.157
View more
  4 in total

1.  Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.

Authors:  Gregory A Light; Wen Zhang; Yash B Joshi; Savita Bhakta; Jo A Talledo; Neal R Swerdlow
Journal:  Neuropsychopharmacology       Date:  2017-04-20       Impact factor: 7.853

2.  Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.

Authors:  Veronica B Perez; Melissa Tarasenko; Makoto Miyakoshi; Sean T Pianka; Scott D Makeig; David L Braff; Neal R Swerdlow; Gregory A Light
Journal:  Neuropsychopharmacology       Date:  2017-01-31       Impact factor: 7.853

3.  Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia.

Authors:  Juan L Molina; Michael L Thomas; Yash B Joshi; William C Hochberger; Daisuke Koshiyama; John A Nungaray; Lauren Cardoso; Joyce Sprock; David L Braff; Neal R Swerdlow; Gregory A Light
Journal:  Transl Psychiatry       Date:  2020-11-23       Impact factor: 6.222

4.  Assessing the Relationship between Sense of Agency, the Bodily-Self and Stress: Four Virtual-Reality Experiments in Healthy Individuals.

Authors:  Yonatan Stern; Danny Koren; Renana Moebus; Gabriella Panishev; Roy Salomon
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.